https://orcid.org/0000-0003-1513-336X
References
- Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood, the Journal of the American Society of Hematology. 2019;133(16):1703–1714.
- Hristov AC, Tejasvi T, Wilcox R. Cutaneous T‐cell lymphomas: 2021 update on diagnosis, risk‐stratification, and management. Am J Hematol. 2020;95(10):1209–1213.
- Broccoli A, Zinzani PL. Peripheral T-cell lymphoma, not otherwise specified. Blood, the Journal of the American Society of Hematology. 2017;129(9):1103–1112.
- Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma. Blood, the Journal of the American Society of Hematology. 2011; 117(25):6756–6767.
- Bates SE, Geskin LJ. Romidepsin therapy over 5 years in a clinical setting—real-world experience. JAMA Oncol. 2016; 2(6):794–795.
- Geskin L, Malone DC. An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma. J Dermatolog. Treat. 2017;29(5):522–530.
- Harrison SJ, Bishton M, Bates SE, et al. A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®). Epigenomics. 2012;4(5):571–589.
- Istodax (romidepsin) [package insert]. Summit, NJ: Celgene Corporation; 2014.
- Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res. 2002;8(3):718–728.
- Marshall JL, Rizvi N, Kauh J, et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol. 2002;2(6):325–332.
- Byrd JC, Marcucci G, Parthun MR, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood. 2005;105(3):959–967.
- Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res. 2006;12(12):3762–3773.
- Foss F, Coiffier B, Horwitz S, et al. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. Biomark Res. 2014;2(1):16.
- Noonan AM, Eisch RA, Liewehr DJ, et al. Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel. Clin Cancer Res. 2013;19(11):3095–3104.
- Cabell C, Bates S, Piekarz R, et al. Systematic assessment of potential cardiac effects of the novel histone deacetylase (HDAC) inhibitor romidepsin. Blood. 2009;114(22):3709–3709.